{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"145"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"181"}],"units":"Participants"}],"description":"A complete remission (CR) requires the following: an absolute neutrophil count (segs and bands) \\> 1500/μl, no circulating blasts, platelets \\> 100,000/μl; bone marrow cellularity \\> 20% with trilineage hematopoiesis, and \\< 5% marrow blast cells, none of which appear neoplastic. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement).","groups":[{"description":"See detailed description","id":"OG000","title":"Phase I - Alemtuzumab and Combination Chemotherapy"},{"description":"See detailed description","id":"OG001","title":"Phase II - Alemtuzumab and Combination Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Three participants were deemed ineligible and excluded from this analysis.","reportingStatus":"POSTED","timeFrame":"9 years","title":"Number of Participants Achieving Complete Remission","type":"POST_HOC","unitOfMeasure":"participants"}